Reviewing statin therapy in diabetes--towards the best practise.
Statin therapy is considered critical both in primary and secondary prevention of cardiovascular disease in diabetes. Cholesterol Treatment Trialists' Collaborators meta-analysis of 14 randomised trials of statins in 18686 people with diabetes provides the latest and largest evidence showing a significant 21% reduction in major vascular events per mmol/l reduction in LDL cholesterol. Importantly, the risk reduction was similar in both types of diabetes. Growing evidence supports the view that statin therapy reduces microvascular complications as well. This review updates the current knowledge of statin therapy in preventing micro- and macrovascular complications in both type 1 and type 2 diabetes.
Matikainen
Niina
N
Department of Medicine, University of Helsinki, Finland.
Kahri
Juhani
J
Taskinen
Marja-Riitta
MR
D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D048909:Diabetes Complications / Q000188:drug therapy* / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000517:prevention & control; D003929:Diabetic Neuropathies / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000517:prevention & control; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D014652:Vascular Diseases / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors